CN119546300A - 血中ldl胆固醇降低剂 - Google Patents

血中ldl胆固醇降低剂 Download PDF

Info

Publication number
CN119546300A
CN119546300A CN202380054016.8A CN202380054016A CN119546300A CN 119546300 A CN119546300 A CN 119546300A CN 202380054016 A CN202380054016 A CN 202380054016A CN 119546300 A CN119546300 A CN 119546300A
Authority
CN
China
Prior art keywords
salt
solvate
blood
benzoxazol
methoxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380054016.8A
Other languages
English (en)
Chinese (zh)
Inventor
谷川亮平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN119546300A publication Critical patent/CN119546300A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380054016.8A 2022-07-15 2023-07-14 血中ldl胆固醇降低剂 Pending CN119546300A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-113930 2022-07-15
JP2022113930 2022-07-15
PCT/JP2023/025980 WO2024014524A1 (ja) 2022-07-15 2023-07-14 血中ｌｄｌコレステロール低下剤

Publications (1)

Publication Number Publication Date
CN119546300A true CN119546300A (zh) 2025-02-28

Family

ID=89536850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380054016.8A Pending CN119546300A (zh) 2022-07-15 2023-07-14 血中ldl胆固醇降低剂

Country Status (8)

Country Link
US (1) US20260014122A1 (https=)
EP (1) EP4556006A4 (https=)
JP (1) JPWO2024014524A1 (https=)
KR (1) KR20250034041A (https=)
CN (1) CN119546300A (https=)
JO (1) JOP20250007A1 (https=)
TW (1) TW202408500A (https=)
WO (1) WO2024014524A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) * 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20240277745A1 (en) * 2021-05-27 2024-08-22 Kowa Company, Ltd Pemafibrate and/or tofogliflozin for use in treating liver disease

Also Published As

Publication number Publication date
WO2024014524A1 (ja) 2024-01-18
KR20250034041A (ko) 2025-03-10
JOP20250007A1 (ar) 2025-01-13
EP4556006A4 (en) 2026-01-07
TW202408500A (zh) 2024-03-01
EP4556006A1 (en) 2025-05-21
US20260014122A1 (en) 2026-01-15
JPWO2024014524A1 (https=) 2024-01-18

Similar Documents

Publication Publication Date Title
US12042483B2 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
WO2001022962A1 (en) Anti-hypercholesterolemic drug combination
US8541433B2 (en) Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
EP2114154B1 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
JP2024081650A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
WO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
CN119546300A (zh) 血中ldl胆固醇降低剂
JP6454436B1 (ja) ペマフィブラートを含有する医薬
US20240293369A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN107072996A (zh) 血脂异常症治疗剂
US20210290580A1 (en) New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
JPWO2019236757A5 (https=)
US20080132561A1 (en) Materials and Methods for Treating Hypercholesterolemia
WO2006083214A1 (en) Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
US20100305074A1 (en) Niacin-based pharmaceutical compositions
WO2022224962A1 (ja) 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬
TW202408499A (zh) 降低血中肌肉生長抑制素之藥劑
WO2006090756A1 (ja) 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用
KR20050008745A (ko) Ａｔｐ 시트르산 리아제의 발현 억제용 의약 조성물 및이의 용도
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法
US20050234124A1 (en) Carboxyalkylether-ACAT inhibitor combinations
CA2413906A1 (en) Carboxyalkylether-acat inhibitor combinations
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤
JP2007308484A (ja) 高脂血症の予防及び／又は治療のための医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination